24987-379 : Fortaz 170 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution
NDC: | 24987-379 |
Labeler: | Covis Pharmaceuticals, Inc. |
Product Type: | Human Prescription Drug |
Drug Name: | Fortaz |
Dosage Form: | Intramuscular; Intravenous Injection, Powder, for Solution |
Application #: | NDA050578 |
Rev. Date: |
NDC Package Codes:
- 24987-379-34: 10 VIAL, SINGLE‑DOSE IN 1 TRAY (24987‑379‑34) > 60 ML IN 1 VIAL, SINGLE‑DOSE
Active Ingredients:
- Ceftazidime
Dosage Strength:
- 170 mg/mL
Pharmaceutical Classes:
- Cephalosporin Antibacterial [EPC]
- Cephalosporins [Chemical/Ingredient]
Related Products:
Based on records with the same trade name.- 24987-377 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Covis Pharmaceuticals, Inc.
- 24987-378 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Covis Pharmaceuticals, Inc.
- 24987-382 Fortaz 200 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Covis Pharmaceuticals, Inc.
- 24987-412 Fortaz 20 mg/ml Intravenous Injection, Solution by Covis Pharmaceuticals, Inc.
- 24987-413 Fortaz 40 mg/ml Intravenous Injection, Solution by Covis Pharmaceuticals, Inc.
- 24987-434 Fortaz 56 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Covis Pharmaceuticals, Inc.
- 24987-435 Fortaz 111 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Covis Pharmaceuticals, Inc.
- 0173-0377 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline LLC
- 0173-0378 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline LLC
- 0173-0434 Fortaz 20 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline LLC
- 0173-0435 Fortaz 20 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline LLC
- 51952-016 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 51952-017 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 51952-018 Fortaz 170 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 51952-019 Fortaz 200 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 51952-020 Fortaz 56 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 51952-021 Fortaz 111 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
- 52565-105 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Teligent Pharma, Inc.
- 52565-106 Fortaz 100 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Teligent Pharma, Inc.
- 52565-107 Fortaz 170 mg/ml Intramuscular; Intravenous Injection, Powder, for Solution by Teligent Pharma, Inc.
- More related products ...
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 24987-378Next: 24987-382 >
Related Discussions:
CEFTAZIDIME PRODUCT MONOGRAPH
PLEASE CEFTAZIDIME complete information as early as possible. ## Ceftazidime is usually reserved for the treatment of in... 1 reply
PLEASE CEFTAZIDIME complete information as early as possible. ## Ceftazidime is usually reserved for the treatment of in... 1 reply
Side effects of Fortaz
How long do the side effects of Fortaz last after you stop taking it? ## Hi Mary - I did not find specific information a... 1 reply
How long do the side effects of Fortaz last after you stop taking it? ## Hi Mary - I did not find specific information a... 1 reply
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.